advertisement
11.14 Investigational drugs; pharmacological experiments (52)
Showing records 1 to 25
Display all abstracts in classification 11.14 Investigational drugs; pharmacological experiments
Search within classification 11.14 Investigational drugs; pharmacological experiments75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Giannaccini M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267
75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Serle JB
American Journal of Ophthalmology 2018; 186: 116-127
75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Kim J
Journal of Controlled Release 2018; 269: 45-51
75045 Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
Williams PA
Journal of Glaucoma 2017; 26: 1161-1168
75170 Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules
Yu AK
Human Molecular Genetics 2017; 26: 4929-4936
75286 Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits
Loma P
Journal of optometry 2018; 11: 69-74
75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Pfeiffer N
PLoS ONE 2017; 12: e0188899
75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Weinreb RN
Journal of Glaucoma 2018; 27: 7-15
75286 Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits
Guzman-Aranguez A
Journal of optometry 2018; 11: 69-74
75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Voykov B
PLoS ONE 2017; 12: e0188899
75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Kudisch M
Journal of Controlled Release 2018; 269: 45-51
75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Liebmann JM
Journal of Glaucoma 2018; 27: 7-15
75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Katz LJ
American Journal of Ophthalmology 2018; 186: 116-127
75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Usai A
Cellular and Molecular Life Sciences 2018; 75: 1255-1267
75045 Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
Harder JM
Journal of Glaucoma 2017; 26: 1161-1168
75170 Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules
Datta S
Human Molecular Genetics 2017; 26: 4929-4936
75045 Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
John SWM
Journal of Glaucoma 2017; 26: 1161-1168
75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Renieri G
PLoS ONE 2017; 12: e0188899
75170 Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules
McMackin MZ
Human Molecular Genetics 2017; 26: 4929-4936
75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Chiellini F
Cellular and Molecular Life Sciences 2018; 75: 1255-1267
75286 Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits
de Lara MJP
Journal of optometry 2018; 11: 69-74
75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
McLaurin E
American Journal of Ophthalmology 2018; 186: 116-127
75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Martin KR
Journal of Glaucoma 2018; 27: 7-15
75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
da Silva NRK
Journal of Controlled Release 2018; 269: 45-51
75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Kaufman PL
Journal of Glaucoma 2018; 27: 7-15
